Navigation Links
Tailoring diabetes treatment to older patients yields dramatic results
Date:7/8/2013

More than a quarter of over 70s with type 2 diabetes could benefit simply from improving communication and education in the clinic, new research has revealed. A study led by the University of Exeter Medical School and published in The Lancet found that 27 percent achieved better glycaemic control through individualised care alone.

At the moment, patients over the age of 70 are treated using a blanket method of aggressively reducing blood glucose levels, but that does little to take their complex needs into account.

Dr David Strain, from the University of Exeter Medical School, who led the study, said: "People over the age of 70 are more likely to have multiple complications, such as heart disease, as well as type 2 diabetes. Yet perversely, these patients have so far been excluded from clinical trials, precisely because of these complications. It means they are generally treated with a 'one-size-fits-all' approach. We found that simply by individualising goals and setting realistic targets, then spending time talking to patients rather than aggressively chasing targets resulted in nearly a quarter of patients achieving better glycaemic control, without the need for medication."

Type 2 diabetes is one of the most common chronic disorders in older adults. The number of people over the age of 65 has grown worldwide, and could now be as high as one in five. Older patients are more susceptible to complications caused by hyperglycaemia, when blood sugar levels are not properly balanced. These complications can increase the risk of falls and dizziness.

The situation has led to calls for treatment to be individualised, but so far evidence to support the case has been lacking. The research was funded by Novartis Pharma AG, the company that produces the antihypertensive agent vildagliptin. In the study, 139 patients from across Europe were given 50mg of the drug twice a day, while the same number of comparable patients were given a placebo, plus individualised care. All patients were over the age of 70, and were included in the trial because their GP thought they needed more medication. The findings were stark: those patients who were given the drug were three times more likely to reach their target than those who were not involved in the study, and received standard treatment. But researchers were particularly excited by the result from the placebo group, in which 27 percent met their targets without any medication.

Dr Strain said: "This was a small trial, but the results were quite dramatic, and it is the first strong evidence that individualised care can make a huge difference to the lives of older patients with type 2 diabetes. We now need to build on this evidence with further research."


'/>"/>

Contact: Louise Vennells
l.vennells@exeter.ac.uk
44-013-927-24927
University of Exeter
Source:Eurekalert

Related medicine news :

1. First prospective trial shows molecular profiling timely for tailoring therapy
2. Pre-pregnancy diabetes increases risk of MRSA among new mothers
3. UCI researchers awarded $2.27 million to create novel diabetes treatments
4. Huge falls in diabetes mortality in UK and Canada since mid-1990s
5. RSNA: Exercise Benefits Patients with Type 2 Diabetes
6. Exercise benefits patients with type 2 diabetes
7. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
8. Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease
9. Loyola receives $1.5 million grant to study vitamin D for diabetes and depression
10. NYSCF and Columbia researchers demonstrate use of stem cells to analyze causes, treatment of diabetes
11. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin), KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) Now Available in Pharmacies in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... An ... permit amputees to safely ride all types of amusement park rides. , The patent-pending ... the unit is easy to use and could be set up in a matter ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pennsylvania Cable Network (PCN) during the summer of 2016. The program was made ... by the United States Department of Health and Human Services Administration. The ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate that ...
(Date:12/8/2016)... ... ... David J. Dykeman , Ginger Pigott , and J. Rick ... West, Dec. 12, 2016, at the Fairmont Newport Beach in California. Greenberg Traurig is ... Sciences & Medical Technology Group have been featured speakers at every DeviceTalks conference since ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... KEY FINDINGS North America ... market in 2016 and is expected to continue in ... a large number of surgical procedures that are taking ... in the patient temperature management market.) Patient warming and ... of blood during surgeries, lowering the risks of neurological ...
(Date:12/8/2016)... , Dec 8, 2016 Research and ... Market Analysis and Trends - Adhesion Type, Application, Usability - Forecast ... ... Global Cardiology Electrodes Market is poised to grow at a CAGR ... trends that the market is witnessing include advancements in extracellular microelectrode ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
Breaking Medicine Technology: